Human papillomaviruses are causative agents in 5% of all cancers, including the majority of ano-13 genital and oropharyngeal cancers. Downregulation of innate immune genes (IIGs) by HPV to 14 promote the viral life cycle is well documented; E6 and E7 are known repressors of these genes. 15
genome and generated N/Tert-1 cells stably maintaining the HPV16 genomes. We demonstrate 19 that E6 or E7 individually are not sufficient to repress IIG expression in the context of the entire 20 HPV16 genome, both are required for a synergistic repression. The DNA damage response 21 (DDR) is activated by HPV16 irrespective of E6 and E7 expression, presumably due to viral 22 replication; E1 is a known activator of the DDR. In addition, replication stress was apparent in the 23 HPV16 positive cells lacking E6 and E7, manifested by attenuated cellular growth and activation 24 of replication stress genes. These studies lead us to the following model. Viral replication per se 25 can activate the DDR following infection, and this activation is a known inducer of IIG expression 26 which could induce cellular senescence. To combat this, E6 and E7 synergistically combine to 27 manipulate the DDR and actively repress innate immune gene expression promoting cellular 28 growth; neither protein by itself is able to do this. 29
Importance 30
The role of HPV16 in human cancers is well established; however, to date there are no anti-viral 31 therapeutics that are available for combatting these cancers. To identify such targets, we must 32 enhance understanding of the viral life cycle. Innate immune genes (IIGs) are repressed by 33 HPV16, and we have reported that this repression persists through to cancer. Reversal of this 34 repression would boost the immune response to HPV16 positive tumors, an area that is becoming 35 more important given the advances in immunotherapy. This report demonstrates that E6 and E7 36 synergistically repress IIG expression in the context of the entire HPV16 genome. Removal of 37 Introduction 42 HPV is the most common sexually-transmitted infection in the United States, with an 43 estimated 80% of sexually active adults acquiring an HPV infection in their lifetime (1). Of the 44 high-risk HPVs known to be causative in the development of cancer, HPV16 is the most prevalent 45 genotype (2). HPV16 is causative in around 50% of cervical cancers and nearly 90% of HPV-46 related head and neck squamous cell carcinomas (HPV+HNSCCs) . Further understanding of 47 HPV16 and its life cycle is needed in order to develop novel anti-viral therapies targeting HPV16. 48
Much has been discovered relating to the viral oncoproteins E6 and E7 driving cellular 49 growth and promoting infection (3) (4) (5) (6) (7) (8) (9) . Most well-known are the targeting of cellular p53 and pRb 50 by E6 and E7, respectively. E6 facilitates the degradation of p53 through its association with 51 E6AP, a component of the ubiquitin-degradation pathway, whereas E7 binds to and disrupts the 52 functions of pRb. The viral life cycle is dependent upon the differentiation program of epithelia; 53 together E6 and E7 uncouple the process of differentiation and exit from the cell cycle to allow 54 the virus to replicate and generate progeny virus. 55
In addition to targeting cellular proteins, both E6 and E7 can regulate transcription from 56 the host genome of infected cells (6, 7, (10) (11) (12) . Among the genes targeted for repression by E6 57 and E7 are the innate immune genes (11) (12) (13) (14) (15) (16) . Both viral oncoproteins have been shown to target 58 expression of these genes, and such repression would promote viral infection by an overall 59 suppression of the host immune response. In these studies, E6 and E7 have been over expressed 60 from heterologous promoters. HPV16 infected cells also have an active DNA damage response 61 (DDR) turned on at all times; E6, E7 and E1 have all been shown to activate this pathway (17-62 27) . This provides another challenge the virus must overcome, as activation of the DDR stimulates 63 the innate immune response (28). The DDR-mediated activation of the interferon response can 64 occur in the absence of detectable foreign nucleic acids, such as following treatment of cells with 65 etoposide. (29) . Recently we demonstrated that repression of IIGs by HPV16 persists in HPV16 66 positive tumors and that this repression could contribute to the immune evasion by the HPV16 67 tumor (30, 31) . We also recently demonstrated that, as well as E6 and E7, E2 can also repress 68 expression of IIGs (30) . Given that all of the IIG studies with E6, E7 and E2 have been done with 69 over-expression of the viral proteins from heterologous promoters, we sought to investigate the 70 contribution of each viral protein to IIG repression in the context of the entire HPV16 genome. 71
In order to investigate the contribution of the individual viral proteins to IIG repression, we 72 generated mutant HPV16 genomes that had stop codons in E6 or E7, or both (see materials and 73 methods). These were transfected into the hTERT immortalized foreskin keratinocyte cell line 74 N/Tert-1 to establish stable cell lines containing wild type HPV16 and the assorted E6/E7 mutants. 75
We have demonstrated that HPV16 represses IIGs in these cells (30, 31) . These experiments 76 required the use of already immortalized keratinocytes as HPV16 cannot immortalize primary 77 keratinocytes in the absence of E6 and E7 expression. The results demonstrate that in the 78 absence of either E6 or E7 there is an activation of IIG expression, not a repression. Removal of 79 expression of both oncoproteins resulted in an additive activation of IIG expression. Strikingly, 80
there is a strong synergism between E6 and E7 to repress IIGs as both proteins together can 81 repress IIG expression in the context of cells containing the entire HPV16 genome. As HPV16 is 82 known to activate the DDR, and an active DDR can activate expression of IIGs (28), we 83 investigated the DDR in the wild type and mutant HPV16 genomes. We observed that the DDR 84 is active in all HPV16 containing cells demonstrating that neither E6 nor E7 is required for 85 activation of the DDR by HPV16. This activation likely results from the expression of E1 which is 86 a known activator of the DDR (23, (25) (26) (27) . We cannot generate stable cell lines over-expressing 87 E1 by itself as it is toxic to cells. In addition, the cells lacking both E6 and E7 expression had 88 severely attenuated cellular growth. All cells had activation of genes involved in managing 89 replication stress. The results demonstrate that E6 and E7 synergize to repress expression of 90
IIGs. They also demonstrate that activation of the DDR and induction of replication stress can 91 occur in HPV16 cells independently of E6 and E7 expression, probably due to the replication 92 factor E1. 93
Results 94

Establishment and characterization of mutant HPV16 genome N/Tert-1 cells 95
We introduced stop codons for E6 (residue C 110 mutated to a T) or E7 (residue T 584 96 mutated to an A) into the HPV16 genome, and both together. We prepared stable pooled N/Tert-97 1 cell lines containing the wild type and mutant HPV16 genomes. These were named N/Tert-98 1+HPV16, N/Tert-1+HPV16 E6 STOP, N/Tert-1+HPV16 E7 STOP and N/Tert-1+HPV16 E6E7 99 STOP. The presence of HPV DNA in the cells was confirmed by PCR using E6, E2 and E5 primers 100 ( Fig. 1A) . While there was less DNA present in the mutants, levels were within 2-fold of each other 101 between the different cell lines. The detection of E6, E2 and E5 demonstrates an intact early 102 region in these cells. We next investigated RNA expression from the viral genome in these cell 103 lines using qRT-PCR ( Fig. 1B ). There was less RNA present in the N/Tert-1+HPV16 E6E7 STOP 104 cells indicating that these viral oncoproteins may actually promote transcription from the HPV16 105 genomes. However, in all cell lines there was significant expression of the viral genes and again, 106 this was across the entire early region as E6, E2 and E5 expression is detected. 107
As markers for E6 and E7 activity, the expression levels of p53 and pRb were investigated 108 ( Fig. 1C ). Both p53 and pRb are decreased in N/Tert-1+HPV16 cells and p53 levels are rescued 109 to the same level as the parental N/Tert-1 cells in the E6 STOP and E6E7 STOP genomes. pRb 110 is elevated when E7 is absent (E7 STOP), as would be expected. Surprisingly, pRb was down-111 regulated in N/Tert-1+HPV16 E6/E7 STOP cells. We confirmed that the E7 was mutated in these 112 cells by DNA sequencing to eliminate the possibility of a plasmid mix up during transfection (not 113 shown). These cells are stressed and have very slow growth (see below), therefore the presence 114 of the replicating genome in the absence of E6 and E7 targets pRb for down-regulation by an as 115 yet unknown mechanism. These blots were repeated and quantitated ( Fig 1D) . 116
Absence of E6 and E7 expression increases innate immune gene expression in 117
HPV16 containing cells 118
Our previous work in N/Tert-1 cells demonstrates that there is down regulation of innate 119 immune gene expression at various stages of the interferon signaling pathway by HPV16 (30, 120 31). Following treatment of cells with interferon there is an activation of ISGF3 (interferon 121 stimulated gene factor 3) which is a complex composed of STAT1, . This 122 transcription factor complex then enters the nucleus and binds to the control elements of 123 interferon stimulated genes (ISGs) to activate their transcription. These ISGs are also 124 downregulated in HPV16 positive N/Tert-1 cells (30, 31) . These genes are repressed by E6, E7 125 and E2 and it was unclear what viral protein is responsible for this repression in the context of the 126 entire HPV16 genome. Therefore, we investigated the expression of ISGs and STAT1-IRF9-127 STAT2 in the mutant genome HPV16 positive N/Tert-1 cells. 128 Fig. 2A demonstrates that the ISGs IFIT1, MX1 and OAS1 are repressed by HPV16 in 129 N/Tert-1 cells, as we have reported (lanes 2, 7, 12). Strikingly, ablation of E6 expression (lanes 130 3, 8,13) or E7 expression (lanes 4, 9, 14) elevates ISG expression higher than that in control 131 N/Tert-1 cells (lanes 1, 6, 11). In addition, ablation of both E6 and E7 expression (lanes 5, 10, 15) 132 results in an additive increase in ISG expression. This regulation of RNA by the HPV16 genomes 133 was reflected in the expression of the MX1 and IFIT1 proteins ( Fig. 2B ). This western blot was 134 repeated and the results quantitated ( Fig. 2C ). These results demonstrate that both the RNA and 135 protein levels of ISGs are elevated in HPV16 containing N/Tert-1 cells that have abrogated E6 136 and E7 expression, when compared with parental control cells. 137
We looked at the expression of the ISGF3 components in the mutant cells ( Figure 3 ). As 138 previously reported, STAT1 and IRF9 are repressed by HPV16 in N/Tert-1 cells, while STAT2 is 139 not (compare lanes 2, 7, 12 with 1, 6, 11) (30, 31). Removal of E6 or E7 abrogates HPV16 140 repression of STAT1 or IRF9 in N/Tert-1 cells. STAT1 RNA levels were elevated in the absence 141 of both E6 and E7 expression (compare lane 10 with 7). Protein expression levels of STAT1 and 142 IRF9 are similarly regulated (Fig. 3B ). Any repression of these proteins is lost following abrogation 143 of E6 or E7 expression. The experiment in Fig. 3B was repeated and the western blots quantitated 144 ( Fig. 3C ). Unlike the large increase in STAT1 RNA (Fig. 3A) , there was no statistically significant 145 difference in STAT1 protein levels in the absence of E6 and E7 when compared with abrogation 146 of either protein expression by itself. 147
To determine whether the activation of STAT1 expression in the absence of E6 and E7 148 was due to an increase in interferon production we monitored the RNA levels for interferon genes. 149
There was no detectable expression of interferon α or β in any of the N/Tert-1 cells. However, 150
there was an increase in interferon κ RNA in the absence of both E6 and E7 expression when 151 compared with parental cells (IFNκ, Fig. 3D ). We previously observed a slight repression of IFNκ 152 in HPV16 positive N/Tert-1 cells that we did not observe here, perhaps due to the use of clonal 153 lines, rather than the pools used here. It is possible that the elevated IFNκ is responsible for the 154 activation of STAT1 expression. 155
The absence of functional E6 and E7 in HPV16 positive N/Tert-1 cells attenuates 156 cellular growth. 157
In doing the above experiments, we noticed that the N/Tert-1+HPV16 E6E7 STOP cells 158 grew slower than the other N/Tert-1 cell lines. To quantitate this, we carried out a growth curve 159 and demonstrated that this was indeed the case (Fig. 4) . The presence of the HPV16 genome 160 and the absence of E6/E7 expression resulted in dramatically attenuated growth when compared 161 with parental N/Tert-1 cells. The N/Tert-1+HPV16 cells grew faster than parental N/Tert-1 cells 162 as expected, and removal of E6 expression did not change this increased expression. The 163 absence of E7 expression reduced the growth rate of the cells to that of the parental N/Tert-1 164 cells. However, the absence of both E6 and E7 synergized to dramatically reduce the growth of 165 the N/Tert-1 cells. 166
The DNA damage response is activated in N/Tert-1 cells irrespective of E6/E7 167
expression. 168
It is well established that HPV16 activates the DNA damage response (DDR) in 169 keratinocytes, and that individual over-expression of E6 or E7 can also activate the DDR (17, 18, 170 20-22, 24, 35, 36) . In addition, the E1 protein has also been shown to activate the DDR (23, 25-171 27) . Given that the activation of the DDR pathway in non-HPV16 containing cells ordinarily results 172 in growth attenuation, we investigated whether the DDR was activated in HPV16 cells in the 173 absence of either E6 or E7 expression, or both. The levels of CHK1 and CHK2 RNA in N/Tert-1 174 cells are elevated by the HPV16 genome irrespective of E6/E7 status (Fig. 5A ). This is reflected 175 at the protein level ( Fig. 5B ). In addition, both CHK1 and CHK2 are activated in HPV16 positive 176 N/Tert-1 cells irrespective of E6 and E7 status, as demonstrated by an increased activating 177 phosphorylation of these proteins. Using immunofluorescence staining, we also observed that 178 levels of γ-H2AX are increased in N/Tert-1 cells containing HPV16 irrespective of E6 and E7 levels 179
These results suggested that the N/Tert-1 cells containing HPV16 were under replication 181 stress irrespective of E6/E7 status of the viral genome. We next investigated the RNA expression 182 pattern of stress response genes in the N/Tert-1 cells containing the HPV16 genomes ( Fig. 6) . HPV in keratinocytes (13, 15, 16, 37) . It is also established that, when E6 and E7 are 195 overexpressed individually in keratinocytes, they can repress expression of innate immune genes 196 (IIGs) (12, (38) (39) (40) . Recently we demonstrated that HPV16 E2 can also repress IIG expression 197 when overexpressed in keratinocytes (30) . Given that all three viral proteins can repress innate 198 immune gene expression when overexpressed, we sought to extend these studies to the HPV16 199 genome. To do this, we generated keratinocytes containing HPV16 with stop codons in either E6 200 or E7, or both together, to abrogate oncoprotein expression, and leaving the expression of E2 201 intact. Given that E6 and E7 are required for the generation of immortalized HPV16 containing 202 primary cells we used foreskin keratinocytes immortalized by hTERT, N/Tert-1, for these 203 experiments (41). Previously we have used these cells to demonstrate that E2 can regulate 204 expression of host genes in keratinocytes, and that this regulation was relevant to the viral life 205 cycle (30). The mutant and wild-type genome containing cell lines generated demonstrated the 206 presence of HPV16 DNA with corresponding RNA expression from the viral genome. The N/Tert-207 1 cells with genomes containing stop codons in E6 or E7 demonstrated the predicted expression 208 of the tumor suppressor proteins p53 and pRb; i.e. p53 is not degraded when E6 is non-functional, 209 and pRb is expressed when E7 is non-functional. However, in the cells containing the genomes 210 with stop codons in both E6 and E7 the levels of Rb are down regulated by an as yet unclear 211 mechanism perhaps related to the replication stress these cells are under (Fig. 1) . 212
We next investigated the expression of interferon stimulated genes (ISGs) in these cell 213 lines and made several striking observations. First, HPV16 represses the expression of ISGs in 214 N/Tert-1 cells, as we have previously reported (30, 31) . Second, in the absence of either E6 or 215 E7 there is an increase in the expression of the ISGs investigated to levels above what is observed 216 in the vector control N/Tert-1 cells. Third, in the absence of both E6 and E7 there is an additive 217 increase in the expression of the ISGs, increasing all of their expression levels to statistically 218 significant higher levels than the parental N/Tert-1 cells. Fourth, this increase in RNA expression 219 is reflected in protein expression; elevated levels of IFIT1 and MX1 in the absence of E6 and E7 220 was observed when compared with parental cells. Fifth, looking at the upstream ISGF-3 complex 221 genes (the complex responsible for activating the ISGs) there is an enhanced increase in STAT1 222 levels when compared to N/Tert-1 cells where E6 and E7 are not expressed, although this is not 223 reflected at the protein level. Sixth, there is an increased expression of IFNκ in the absence of 224 both E6 and E7 when compared with all other N/Tert-1 cell lines. 225
These results demonstrate that, in the absence of E6 and E7, E2 cannot repress IIG 226 expression alone. However, neither E6 nor E7 can repress these genes by themselves therefore 227 there remains the possibility that E2 synergizes with E6 and E7 to repress IIGs in the context of 228 the entire HPV16 genome. It is also possible that E2, E6 and E7 have roles to play in IIG 229 repression during the different stages of the viral life cycle and this is currently under investigation. 230
It is clear that both E6 and E7 are required to suppress innate immune gene expression 231 in the context of the entire HPV16 genome. While both proteins can repress genes when 232 overexpressed individually, abrogation of expression of either results in a loss of innate immune 233 gene repression (Figs. 2-3 ). This demonstrates a previously unidentified synergism between the 234 two viral proteins in the context of the entire HPV16 genome. Both proteins have been shown to 235 target the interferon signaling pathway using different mechanisms. E7 can bind to and inhibit the 236 transactivating function of IRF1 (42), while E6 binds to IRF3 and inhibits its transcriptional activity 237 (43) and can also interfere with JAK-STAT activation by binding Tyk2 (38). Our studies 238 demonstrate that abrogation of both E6 and E7 expression results in an additive increase in the 239 expression of ISGs. Therefore, the cross talk between E6 and E7 to suppress the innate immune 240 response is synergistic, and the additive nature of ISG increase in the absence of these two 241 proteins suggests independent pathways that are targeted by these viral proteins. The results 242 presented here suggest that disruption of the mechanism that either of the viral proteins uses to 243 suppress the innate immune response is a potential therapeutic target that would boost the host 244 immune response against HPV infections. 245
The next question we addressed was what could be responsible for the elevated innate 246 immune gene expression in the absence of E6/E7? The innate immune response is activated by 247 detection of cytoplasmic DNA via the cGAS-STING pathway, cytoplasmic DNA can be detected 248 in cells treated with DNA damaging agents (44). However, HPV16 E7 acts to combat activation 249 of the innate immune response via the cGAS-STING pathway (45). A source for activation of the 250 DDR in HPV16 cells lacking E6 and E7 is the E1 viral helicase that can activate the DDR by itself 251 (23, 25, 26, 46) . Although E6 and E7 can activate the DDR when overexpressed in cells, it is clear 252 that in their absence HPV16 activates DDR pathways and we propose this is mediated by the 253 viral replication factor E1 (Figs. 5&6). This activation of the DDR by HPV16 replication in the 254 absence of E6 and E7 results in activation of the expression of innate immune response genes, 255 perhaps via activation of the cGAS-STING pathway although we could not detect several markers 256 for activation of this pathway in the N/Tert-1+HPV16 E6/E7 STOP cells (not shown). In support 257 of the idea that there is increased aberrant DNA sensing in the absence of E6 and E7, levels of 258
IFNκ are elevated in these cells (Fig. 3) . In addition to activation of the DDR, the N/Tert-1+HPV16 259 E6/E7 STOP cells are under replication stress as demonstrated by an attenuation of cellular 260 growth ( Fig. 4 ) and activation of expression of genes involved in replication stress (Fig. 6) . These 261 same genes can be activated by E7 when it is over expressed by itself (18). Therefore, there are 262 multiple mechanisms that the virus can use to activate the DDR. 263
Altogether, the results presented here prompt us to propose the following model: Following 264 infection viral genome copy number increases from 1 to around 50 copies per cell. This increase 265 in copy number would by itself activate the DDR due to torsional stress on the viral DNA. This 266 activation promotes recruitment of homologous recombination factors to the viral genome, a 267 process required for HPV16 replication (47). The activation of the DDR by external DNA damaging 268 agents results in cell cycle arrest to allow detection of damage and repair of the DNA prior to 269 restarting the cell cycle. HPV16 must circumvent this, as it would prevent amplification of the viral 270 genome. Therefore, E6 and E7 manipulate constituents of the DDR to allow cell cycle progression 271 in the presence of an active DDR (this has been previously demonstrated (17, 18, 35, 36) ), thus 272 preventing cell cycle arrest. Simultaneously, the actions of E6 and E7 repress innate immune 273 response genes and this not only promotes the viral life cycle via immune evasion, but also 274 abrogates the growth inhibitory activity of innate immune signaling. We show, for the first time, 275 that this targeting of the innate immune response by E6 and E7 is totally synergistic in the context 276 of the entire HPV16 genome; neither protein is able to do this by itself. Therapeutically, targeting 277 only one of the pathways used by E6 or E7 would potentially alleviate the repression of the innate 278 immune response and boost the host immune response to HPV16 infection. 279 280 281
Materials and Methods 282
Generation of HPV16 mutant genomes 283
Mutations to introduce T584A (E6 STOP), C110T (E7 STOP) or both C110T and T584A 284 (E6E7 STOP) into HPV16 in the peGFP-N1HPV16 plasmid, were carried out by Genscript. Briefly, 285 the target area was released from rest of the plasmid by EcoNI and NotI restriction digest, base 286 changes introduced and amplified via PCR, which was then religated into the plasmid backbone. 287
Successful mutagenesis was confirmed by sequencing. These mutations resulted in a) an early 288 stop codon in the E6 gene, b) an early stop codon in the E7 gene or c) early stop codon in both 289 E6 and E7 gene ( Figure 5) . 290
Cell culture 291
Cell lines containing the HPV16 genomes were generated using N/Tert-1 as previously 292 described (30, 31). These cells were cultured alongside parental N/Tert-1 for all comparisons. 293 N/Tert-1 and N/Tert-1+HPV16 cells were grown in K-SFM (Invitrogen) with 1% (v/v) 294 penicillin/streptomycin mixture (Thermo Fisher Scientific) containing 4 µg/mL hygromycin B 295 (Millipore Sigma) at 37°C in a 5% CO2/95% air atmosphere and passaged every 3-4 days. Cells 296 containing WT or mutant HPV16 were grown in the same medium also containing 150 μg/mL 297 G418 (Thermo Fisher Scientific). All cells were routinely checked for mycoplasma contamination. 298
To measure cell growth, cells were seeded in triplicate onto 10 cm dishes at a density of 299 3 × 10 5 cells per dish, and grown to 80% confluency (typically 3 days). Cells were then harvested 300 by trypsinization, stained with trypan blue and viable cells counted. 3 × 10 5 cells per dish were re-301 plated and this was repeated 3 times in total. 302 For downstream protein and nucleic acid analysis, 1x10 6 cells were plated onto 100 mm 303 plates, trypsinized and pelleted after 24hrs and washed twice with phosphate buffered saline 304 
DNA was extracted from monolayer grown cells by lysis in HIRT lysis buffer (400 mM 326
NaCl, 10 mM Tris-HCl, and 10 mM EDTA). Cell extracts were incubated with 50 g/ml RNase A, 327 and as well as proteinase K sequentially to remove residual RNA and proteins, followed by 328 phenolchloroform extraction. DNA was resuspended in TE buffer and quantitated by 329 spectrophotometry.Following dilution, 10 ng of DNA and relevant primers were added to PowerUp 330 SYBR Green Master Mix (Applied Biosystems) and real-time PCR performed using 7500 Fast 331
Real-Time PCR System, using sybr green reagent. Primer sequences: HPV16 E2 F 5' 332 atggagactctttgccaacg-3' HPV16 E2 R 5'-tcatatagacataaatccag-3'; HPV16 E6 F 5'-333 ttgaaccgaaaccggttagt-3' HPV16 E6 R 5'-gcataaatcccgaaaagcaa-3'; HPV16 E5 F 5'-334 cacaacattactggcgtgct-3' HPV16 E5 R 5'-acctaaacgcagaggctgct-3'. 335
Protein analysis 336
1x10 6 cells were lysed in 50 µl NP40 lysis buffer (0.5% Nonidet P-40, 50 mM Tris, pH 7.8, 337 150 mM NaCl) supplemented with protease inhibitor (Roche Molecular Biochemicals) and 338 phosphatase inhibitor cocktail (Sigma). The cell and lysis buffer mixture was incubated on ice for 339 20 min, centrifuged for 20 min at 184,000 rfc at 4°C, and supernatant was collected. Protein levels 340
were determined utilizing the Bio-rad protein estimation assay (Bio-rad). Equal amounts of protein 341
were boiled in 2x Laemmli sample buffer (Bio-rad). Samples were then loaded into a Novex 4-342 12% gradient Tris-glycine gel (Invitrogen), run at 100V for approximately 2 hours, and then 343 transferred onto nitrocellulose membranes (Bio-rad) at 30V overnight using the wet blot method. 344
Membranes were blocked in Odyssey blocking buffer (diluted 1:1 with PBS) at room temperature 345 for 6 h and probed with relevant antibody diluted in Odyssey blocking buffer overnight at 4°C. 346
Membranes were then washed with PBS supplemented with 0.1% Tween (PBS-Tween) before 347 probing with corresponding Odyssey secondary antibody (goat anti-mouse IRdye800cw or goat 348 anti-rabbit IRdye680cw) diluted 1:10000 for 1h at 4°C. Membranes were washed in PBS-Tween 349 before infrared scanning using the Odyssey CLx Li-Cor imaging system. The following antibodies 350 were used for western blot analysis at 1:1000 dilutions in Odyssey blocking buffer, diluted 1:1 with Facility, supported, in part, by funding from NIH-NCI cancer center grant P30 CA16059. 363
Immunofluorescence was observed using an LSM 700 Laser Scanning Microscope and ZEN 364 2011 software (Carl Zeiss). Images were assembled in Adobe Photoshop CS 6.0. 365
Statistics 366
Standard error was calculated from at least three independent experiments and significance 367 determined using a student's t-test. To measure cell growth, cells were seeded in triplicate onto 10 cm dishes at a density of 3 × 458 10 5 cells per dish, and grown to 80% confluency (typically 3 days). Cells were then harvested by 459 trypsinization, stained with trypan blue and viable cells counted. 3 × 10 5 cells per dish were re-460 plated and this was repeated 3 times in total. Data represents the average of 3 independent 461 experiments and error bars indicate standard error of the mean. N/Tert-1+HPV16 grew 462 significantly faster than N/Tert-1 and loss of E6 did not affect this. Removal of E7 resulted in the 463 N/Tert-1 cells growing similarly to the parental N/Tert-1. Removal of E6 and E7 resulted in 464 significantly slower growth of N/Tert-1 cells when compared with all other lines. In all analysis, 465
p<0.05 to assign significance. 
